Trial Profile
Phase II study of Neoadjuvant Letrozole for Postmenopausal Women with Endocrine-responsive and Anthracycline non-responsive Breast Cancer (JBCRG-06).
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 23 Nov 2019
Price :
$35
*
At a glance
- Drugs Letrozole (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- 17 Jun 2013 Status changed from suspended to discontinued as reported by University Hospital Medical Information Network - Japan record.
- 29 Nov 2011 Status changed from active, no longer recruiting to suspended as reported by University Hospital Medical Information Network - Japan.
- 22 Feb 2011 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.